Yasuhiro Maeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yasuhiro Maeda has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Terufumi Yamaguchi
12 shared publicationsAkihisa Kanamaru
Division of HematologyDepartment of Internal Medicine, Kinki University School of Medicine, Osaka, Japan
9 shared publicationsChikara Hirase
7 shared publications- Jun-Ichi Miyatake
Division of Hematology and Rheumatology, Department of Internal Medicine, Kinki University Faculty of Medicine, Japan
5 shared publications - Mitsuhiro Matsuda
Division of Hematology, Nephrology and Rheumatology, Department of Internal Medicine, Kinki University School of Medicine, Osaka 589-8511, Japan
4 shared publications Miyako Tanaka
Division of HematologyDepartment of Internal Medicine, Kinki University School of Medicine, Osaka, Japan
4 shared publications
Latest Publications
- Open Access
- 10 January 2015
- Published by Sciencedomain International in International Journal of Medical and Pharmaceutical Case Reports
- Vol. 2 (3) , 57-60
Successful Treatment with Dapsone for Refractory Immune Thrombocytopenia
In adult with immune thrombocytopenia (ITP), it has been known that steroids have been used as a first-line therapy. The therapy induced remission in more than 60% of patients. Here, we evaluated the results of dapsone for a steroid-resistant ITP patient. Further, dapsone has been reported to emerge as a safe and inexpensive therapy for chronic ITP. In this case, we showed a relationship between platelet count and grade of hemolysis by treatment with dapsone.
- 10 January 2015
- Published by Sciencedomain International in International Journal of Medical and Pharmaceutical Case Reports
- Vol. 2 (3) , 57-60
Open AccessSuccessful Treatment with Dapsone for Refractory Immune Thrombocytopenia
In adult with immune thrombocytopenia (ITP), it has been known that steroids have been used as a first-line therapy. The therapy induced remission in more than 60% of patients. Here, we evaluated the results of dapsone for a steroid-resistant ITP patient. Further, dapsone has been reported to emerge as a safe and inexpensive therapy for chronic ITP. In this case, we showed a relationship between platelet count and grade of hemolysis by treatment with dapsone.
- 24 January 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 1947-1952
Clinical importance of human herpes virus-8 and human immunodeficiency virus infection in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin lymphoma that usually develops in immunosuppressed patients infected with human herpes virus-8 (HHV-8) in conjunction with human immunodeficiency virus (HIV) infection. However, there are several reports of HHV-8-related HIV-negative cases and HHV-8-unrelated HIV-negative cases, mainly in immunodeficient and elderly patients. Here, we report one case of HHV-8-related HIV-negative PEL with gastric cancer (case 1) and one case of HHV-8-unrelated HIV-negative effusion-based lymphoma (case 2), both in elderly men. A 73-year-old man and a 79-year-old man were admitted because of lymphomatous effusions, and no mass was detectable in both cases. They were diagnosed as having malignant effusion lymphoma on the basis of cytological findings indicating atypical lymphoid cells and the expression of CD20 and CD79a. To detect evidence of HHV-8 infection in neoplastic cells, immunocytochemical staining for ORF73/ latent nuclear antigen-1 (LNA-1) was performed. The results revealed that case 1 was ORF73-positive, and case 2 was ORF73-negative. Rituximab-based chemotherapy (R-THPCOP: rituximab, pirarubicin, cyclophosphamide, vincristine, prednisolone) was administered to both patients and complete remission was achieved in both. Compared to most HIV-positive PEL cases, these two cases showed a good response to chemotherapy. In cases of PEL, we should focus on HHV-8 infection and HIV status for determining prognosis.
- 24 January 2013
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (9) , 1947-1952
Clinical importance of human herpes virus-8 and human immunodeficiency virus infection in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin lymphoma that usually develops in immunosuppressed patients infected with human herpes virus-8 (HHV-8) in conjunction with human immunodeficiency virus (HIV) infection. However, there are several reports of HHV-8-related HIV-negative cases and HHV-8-unrelated HIV-negative cases, mainly in immunodeficient and elderly patients. Here, we report one case of HHV-8-related HIV-negative PEL with gastric cancer (case 1) and one case of HHV-8-unrelated HIV-negative effusion-based lymphoma (case 2), both in elderly men. A 73-year-old man and a 79-year-old man were admitted because of lymphomatous effusions, and no mass was detectable in both cases. They were diagnosed as having malignant effusion lymphoma on the basis of cytological findings indicating atypical lymphoid cells and the expression of CD20 and CD79a. To detect evidence of HHV-8 infection in neoplastic cells, immunocytochemical staining for ORF73/ latent nuclear antigen-1 (LNA-1) was performed. The results revealed that case 1 was ORF73-positive, and case 2 was ORF73-negative. Rituximab-based chemotherapy (R-THPCOP: rituximab, pirarubicin, cyclophosphamide, vincristine, prednisolone) was administered to both patients and complete remission was achieved in both. Compared to most HIV-positive PEL cases, these two cases showed a good response to chemotherapy. In cases of PEL, we should focus on HHV-8 infection and HIV status for determining prognosis.
- Open Access
- 26 October 2011
- Published by IntechOpen
Retrovirus Infection and Retinoid
Retrovirus Infection and Retinoid | InTechOpen, Published on: 2011-10-26. Authors: Yasuhiro Maeda, Masaya Kawauchi, Chikara Hirase, et
- 26 October 2011
- Published by IntechOpen
Open AccessRetrovirus Infection and Retinoid
Retrovirus Infection and Retinoid | InTechOpen, Published on: 2011-10-26. Authors: Yasuhiro Maeda, Masaya Kawauchi, Chikara Hirase, et
- Open Access
- 6 June 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (S1) , A31-1
Cellular senescence induction by retinoid on adult T-cell leukemia cells
- 6 June 2011
- Published by Springer Nature in Retrovirology
- Vol. 8 (S1) , A31-1
Open AccessCellular senescence induction by retinoid on adult T-cell leukemia cells
- 11 November 2010
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (1) , 150-152
Senescence induction therapy for the treatment of adult T-cell leukemia
- 11 November 2010
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (1) , 150-152
Senescence induction therapy for the treatment of adult T-cell leukemia
- 1 October 2009
- Published by Taylor & Francis in Hematology
- Vol. 14 (5) , 266-270
Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of rapamycin in myelodysplastic syndrome
We previously reported mRNA expression of glutathione S-transferases theta (GSTT)-1, wild type (623 bp) and mutant (500 bp), in patients with myelodysplastic syndrome (MDS). The deletion of 123 bp creates a sequence that is homologous to the mammalian target of rapamycin (mTOR). To analyze the function of mutant GSTT-1 gene, stable transformants for the mutant and wild-type GSTT-1 gene, respectively, were established. In this study, the expression of the wild and mutant type of the GSTT-1 gene of those stable transformants in cell lines and in bone marrow cells from MDS patients by reverse-transcription polymerase chain reaction (RT-PCR) was observed in the presence or absence of rapamycin. Significant growth inhibition by rapamycin was observed among stable transformants for the mutant GSTT-1 gene, but not wild type GSTT-1 gene, and was indicative of typical apoptosis.
- 1 October 2009
- Published by Taylor & Francis in Hematology
- Vol. 14 (5) , 266-270
Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of rapamycin in myelodysplastic syndrome
We previously reported mRNA expression of glutathione S-transferases theta (GSTT)-1, wild type (623 bp) and mutant (500 bp), in patients with myelodysplastic syndrome (MDS). The deletion of 123 bp creates a sequence that is homologous to the mammalian target of rapamycin (mTOR). To analyze the function of mutant GSTT-1 gene, stable transformants for the mutant and wild-type GSTT-1 gene, respectively, were established. In this study, the expression of the wild and mutant type of the GSTT-1 gene of those stable transformants in cell lines and in bone marrow cells from MDS patients by reverse-transcription polymerase chain reaction (RT-PCR) was observed in the presence or absence of rapamycin. Significant growth inhibition by rapamycin was observed among stable transformants for the mutant GSTT-1 gene, but not wild type GSTT-1 gene, and was indicative of typical apoptosis.
- 1 February 2009
- Vol. 50 (2) , 113-5
[Diffuse large B-cell lymphoma presenting with hypoglossal nerve palsy and great occipital neuralgia].
A 74-year-old man was hospitalized with hypoglossal nerve paralysis and severe great occipital neuralgia. Enhanced MRI of the head showed tumor on the left petrous bone, which compressed the medulla oblongata. Soluble IL-2 receptor was elevated and malignant lymphoma was clinically diagnosed. PET-CT demonstrated a single hot spot on the spleen. After radiation therapy to the lesion on the petrous bone, splenectomy was performed. Pathological findings established a diagnosis of diffuse large B-cell lymphoma. After chemotherapy consisting of rituximab and THP-COP, complete remission was achieved.
- 1 February 2009
- Vol. 50 (2) , 113-5
[Diffuse large B-cell lymphoma presenting with hypoglossal nerve palsy and great occipital neuralgia].
A 74-year-old man was hospitalized with hypoglossal nerve paralysis and severe great occipital neuralgia. Enhanced MRI of the head showed tumor on the left petrous bone, which compressed the medulla oblongata. Soluble IL-2 receptor was elevated and malignant lymphoma was clinically diagnosed. PET-CT demonstrated a single hot spot on the spleen. After radiation therapy to the lesion on the petrous bone, splenectomy was performed. Pathological findings established a diagnosis of diffuse large B-cell lymphoma. After chemotherapy consisting of rituximab and THP-COP, complete remission was achieved.
- 31 March 2008
- Published by Elsevier in Leukemia Research
- Vol. 32 (3) , 510-511
Cross-killing phenomenon during induction of cytotoxic activity against autologous leukemic cells or autologous Epstein-Barr virus-transformed lymphoblastoid B-cell line
- 31 March 2008
- Published by Elsevier in Leukemia Research
- Vol. 32 (3) , 510-511
Cross-killing phenomenon during induction of cytotoxic activity against autologous leukemic cells or autologous Epstein-Barr virus-transformed lymphoblastoid B-cell line
- 15 November 2007
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 134 (6) , 673-677
Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia
We previously reported that all-trans retinoic acid (ATRA) inhibited growth in human T-cell leukemia virus type I (HTLV-I)-positive T-cell lines and in fresh cells from patients with adult T cell leukemia (ATL). Here, we confirmed the clinical effects of ATRA in 20 patients with ATL. The 20 patients (n = 20) with a median age of 56 (range 35–73) years who were diagnosed with ATL received ATRA orally. The efficacy of treatment was as follows: no complete response (CR), a partial response (PR) in 40% of the patients, no change (NC) in 45% of the patients, and a progressive disease (PD) in 15% of the patients. In seven acute-type ATL patients, a PR was achieved in two (28.5%), NC was observed in two (28.5%), and a PD was observed in three (42.8%). In three lymphoma-type ATL patients, a PR (100%) was achieved. Among four chronic-type ATL patients, a PR was achieved in one (25%) and NC was observed in the remaining three (75%). In six smoldering-type ATL patients, a PR was achieved in two (33.3%) and NC was observed in four (66.6%). The major side effects were headache (n = 5), transient liver dysfunction (n = 2), hyperlipidemia (n = 2), and anorexia (n = 1). These results indicated that ATRA might be a useful agent for the safe treatment of ATL.
- 15 November 2007
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 134 (6) , 673-677
Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia
We previously reported that all-trans retinoic acid (ATRA) inhibited growth in human T-cell leukemia virus type I (HTLV-I)-positive T-cell lines and in fresh cells from patients with adult T cell leukemia (ATL). Here, we confirmed the clinical effects of ATRA in 20 patients with ATL. The 20 patients (n = 20) with a median age of 56 (range 35–73) years who were diagnosed with ATL received ATRA orally. The efficacy of treatment was as follows: no complete response (CR), a partial response (PR) in 40% of the patients, no change (NC) in 45% of the patients, and a progressive disease (PD) in 15% of the patients. In seven acute-type ATL patients, a PR was achieved in two (28.5%), NC was observed in two (28.5%), and a PD was observed in three (42.8%). In three lymphoma-type ATL patients, a PR (100%) was achieved. Among four chronic-type ATL patients, a PR was achieved in one (25%) and NC was observed in the remaining three (75%). In six smoldering-type ATL patients, a PR was achieved in two (33.3%) and NC was observed in four (66.6%). The major side effects were headache (n = 5), transient liver dysfunction (n = 2), hyperlipidemia (n = 2), and anorexia (n = 1). These results indicated that ATRA might be a useful agent for the safe treatment of ATL.
- 28 January 2007
- p. 719-23
[Possible therapy with ATRA for adult T-cell leukemia/lymphoma].